TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11267624
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral hydrocortisone
Study: 9884705
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (surgery + radiotherapy)
Study: 7857512
Drug: Hypericum extracts
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extracts (dosage: 300 to 900 mg total extract daily; duration: 2 to 6 weeks)
Study: 2543207
Drug: CAVE chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAVE chemotherapy + RA233
Study: 2543207
Drug: CAVE chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAVE chemotherapy
Study: 29426608
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) at a dose of 10 mg/kg intravenously, 10 min preoperatively and 5 h postoperatively
Study: 26224543
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg once daily, n=125)
Study: 12732880
Drug: G‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF alone (10 mcg/kg/day)
Study: 12732880
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus G‐CSF (Cyclophosphamide at 4 g/m(2) and G‐CSF at 10 mcg/kg/day)
Study: 10199772
Drug: GHRP-2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 plus TRH infusion (1 + 1 microg/kg x h) for 5 days
Study: 348293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, adriamycin, and 5‐fluorouracil (CAF)
Study: 348293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Study: 31286426
Drug: Hand hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand hygiene education programme with digital tools (interactive android-based tablets)
Study: 25982568
Drug: Combined setting
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined setting of one night wake therapy followed by 2 weeks bright light therapy
Study: 25982568
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy alone
Study: 16919506
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy with sustained-release tolterodine alone
Study: 16919506
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy with sustained-release tolterodine combined with behavioral training (pelvic floor muscle exercise training, bladder control techniques, fluid management)
Study: 16919506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug withdrawal and behavioral training stopped)
Study: 16563280
Drug: Weight-adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dose rt-PA (42-92 mg, 1 mg/kg body weight)
Study: 16563280
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rt-PA (42 mg over 90 minutes)
Study: 16563280
Drug: Weight-adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dose rt-PA
Study: 16563280
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rt-PA
Study: 12189776
Drug: Chewing gums
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gums (Superpep forte, 20 mg dimenhydrinate each, chewed for 30 min)
Study: 12189776
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dimenhydrinate tablet
Study: 7851574
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) depot, 1.88 mg
Study: 7851574
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) depot, 3.75 mg
Study: 6935550
Drug: gemfibrozil (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (1600 mg daily)
Study: 25407420
Drug: Food preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food preparation activities
Study: 22431131
Drug: Colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.75 g/day orally
Study: 17211699
Drug: Synbiotic 2000
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic 2000 (once daily dose)
Study: 8729614
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (radiotherapy followed by chemotherapy)
Study: 9802715
Drug: Metronidazole 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 25% dental gel applied subgingivally on days 0 and 7
Study: 27752485
Drug: Mindfulness-integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-integrated cognitive behavior therapy
Study: 22727611
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg coadministered with fimasartan 240 mg
Study: 11788225
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diuretics or beta-blockers)
Study: 7726351
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of 20 ml of 1% lidocaine
Study: 7726351
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of morphine sulfate and midazolam
Study: 7211734
Drug: Full cream
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full cream milk
Study: 7211734
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (skim milk, yoghurt, full cream milk)
Study: 25191915
Drug: Low-dose buprenorphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose buprenorphine
Study: 17267744
Drug: FIR therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR therapy for 1 year
Study: 11254512
Drug: Postmenopausal women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmenopausal women with hormone replacement therapy (HRT)
Study: 7596206
Drug: Other internal
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other internal medicine services
Study: 2551204
Drug: BID regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID regimen (twice a day)
Study: 30418579
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA (2.4 g daily)
Study: 26100924
Drug: 90μg HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90μg HPV vaccine
Study: 26100924
Drug: 60μg HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60μg HPV vaccine
Study: 26100924
Drug: 30μg HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30μg HPV vaccine
Study: 26100924
Drug: Control hepatitis
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hepatitis B vaccine
Study: 20337634
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.i.d. on Day 5 of a 7-day regimen
Study: 20337634
Drug: Laropiprant 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant 40 mg alone
Study: 19298202
Drug: L-diet
Normalized name: ethyl-diethylphosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-diet
Study: 11229106
Drug: prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin GITS 2.5 mg OD
Study: 11229106
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg OD
Study: 11229106
Drug: nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine SR 20 mg BD
Study: 11229106
Drug: enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 5 mg OD
Study: 3497450
Drug: Norfloxacin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (1200 mg)
Study: 3497450
Drug: Cotrimoxazole (480/2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (480/2400 mg)
Study: 29104121
Drug: Vesatolimod (1-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesatolimod (1-, 2-, or 4-mg doses) administered once weekly for 4, 8, or 12 weeks
Study: 29104121
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) administered once weekly for 4, 8, or 12 weeks
Study: 16998266
Drug: Candesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (angiotensin II type 1 receptor blocker)
Study: 16998266
Drug: Amlodipine (dihydropiridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (dihydropiridine calcium antagonist)
Study: 11049913
Drug: Tramadol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2.5 mg/kg (Group 1)
Study: 11049913
Drug: Tramadol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.25 mg/kg + lysine acetyl salicylate 12.5 mg/kg (Group 2)
Study: 9284852
Drug: Compound 48/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound 48/80 (reversed microdialysis)
Study: 1329673
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg injections three times a week for six weeks)
Study: 7818590
Drug: Thymopentin treatment
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin treatment
Study: 3919557
Drug: Bepridil once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil once daily
Study: 31605792
Drug: Comparator (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (EGFR tyrosine kinase inhibitors)
Study: 30442122
Drug: Current practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current practice of BP lowering therapy
Study: 30442122
Drug: Intermediate risk
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate risk threshold for BP lowering therapy
Study: 30442122
Drug: High risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk threshold for BP lowering therapy
Study: 26369526
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg basiliximab with cyclosporine (control)
Study: 26369526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg basiliximab with cyclosporine
Study: 26369526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg basiliximab with everolimus (CNI-free)
Study: 19183087
Drug: Oral amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amitriptyline (10-20 mg/day)
Study: 19183087
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone plus oral amitriptyline (10-20 mg/day)
Study: 15823767
Drug: Mix 75/25
Normalized name: HumaLOG Mix 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix 75/25 plus metformin
Study: 10852983
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day) alone (group A)
Study: 10852983
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day) combined with cyclical etidronate (group B)
Study: 9612103
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and metronidazole combination
Study: 3094172
Drug: Thiamphenicol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol (single oral dose)
Study: 3094172
Drug: Lymecycline (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline (two 1.5-g oral doses taken 12 hr apart)
Study: 30365202
Drug: Cebranopadol (200–1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol (200–1,000 μg)
Study: 30365202
Drug: Morphine prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine prolonged release (PR) (≤120 mg daily)
Study: 30365202
Drug: Cebranopadol and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol and Morphine PR
Study: 28459958
Drug: TRV027 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 1 mg/h
Study: 28986703
Drug: TRV027 (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 (lower doses)
Study: 24214165
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (30 sessions)
Study: 17492582
Drug: SNRIs (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNRIs (selective noradrenaline reuptake inhibitors)
Study: 17492582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavior therapy and SSRIs (selective serotonin reuptake inhibitors)
Study: 17492582
Drug: Adding an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding an SSRI, an SNRI, or an atypical antipsychotic to an SSRI
Study: 12633543
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor captopril
Study: 9181900
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg p.o. daily for six months
Study: 9181900
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg p.o. daily for fourteen days, then reduced to 10 mg for a total treatment period of six months
Study: 8398713
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg qid for 5 days with each course of chemotherapy)
Study: 8398713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy without verapamil)
Study: 3299394
Drug: ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ferrous sulphate (100 mg/day)
Study: 3299394
Drug: ferritin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferritin (80 mg/day as Fe3+)
Study: 3299394
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of ferritin (80 mg Fe3+/day), folinic acid and vitamin B12 coenzyme
Study: 24851692
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rt-PA with catheter-directed thrombolysis
Study: 24851692
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rt-PA with catheter-directed thrombolysis
Study: 22480663
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 50 mg administered 1 hour before each exposure session
Study: 22480663
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before each exposure session
Study: 10510162
Drug: 8 micromol
Normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 micromol min‐1 N‐monomethyl L‐arginine (L‐NMMA)
Study: 8787171
Drug: Cladribine (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (new immunosuppressive drug)
Study: 6404577
Drug: Tiapamil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (200 mg t.i.d.)
Study: 26524699
Drug: 8-week CCR
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week CCR based on Nordic walking training (five times weekly) at 40-70% of maximal heart rate
Study: 22966414
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (Kaneka QH ubiquinol; 300 mg per day)
Study: 17218573
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg/d)
Study: 11156217
Drug: GMK vaccine
Normalized name: GMK vaccine
DrugBank: GMK (DB06661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMK vaccine (30 microg of G(M2)) and GDK (various doses)
Study: 11156217
Drug: GDK (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDK (30 or 70 microg of G(D2))
Study: 11156217
Drug: GDK (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDK (various doses)
Study: 11156217
Drug: GDK (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDK (highest dose level)
Study: 8891621
Drug: Gentamicin 80
Normalized name: gentamicin 80 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 80 mg
Study: 6625729
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 40 mg kg‐1 (Group A)
Study: 6625729
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 20 mg kg‐1 (Group B)
Study: 6625729
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 40 mg kg‐1 (Camps)
Study: 31301057
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy intervention strategies (Group A)
Study: 28708216
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (Group B)
Study: 7995325
Drug: Progesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (300 mg)
Study: 30778667
Drug: 6% L-ascorbate-2-phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% L-ascorbate-2-phosphate trisodium salt (APS) in test lotion (TL)
Study: 30778667
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion (PL)
Study: 29395188
Drug: Naltrexone (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50mg daily for 3 weeks)
Study: 29395188
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 3 weeks)
Study: 27872863
Drug: sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release methylphenidate
Study: 22531559
Drug: Pressure Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure Support Ventilation (PSV) with Sighs (30 cm H2O peak airway pressure, administered once per minute)
Study: 18829790
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum and Lactobacillus acidophilus added to breast milk or mixed feeding, twice daily for 6 weeks
Study: 12425849
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 50% nitrous oxide and oxygen
Study: 12425849
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of air and oxygen (Control)
Study: 31227872
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele at rs2893881
Study: 29308593
Drug: ADF IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADF IR formulation of an opioid
Study: 29308593
Drug: Marketed IR
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed IR formulation
Study: 24777621
Drug: Probiotic food
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic food supplement (Lactobacillus rhamnosus R0011 1.9×10^9 cfu and L. acidophilus R0052 0.1×10^9 cfu/d for 7 days)
Study: 24777621
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oral rehydration solution and zinc)
Study: 24777621
Drug: Probiotic food
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic food supplement
Study: 23586657
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered three times per day for 48 hours
Study: 23586657
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times per day for 48 hours
Study: 21473840
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) before laser preparation
Study: 21473840
Drug: Non-LLT (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LLT (without low level laser therapy) before laser preparation
Study: 19770393
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg, n=26
Study: 17324738
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg (n = 18)
Study: 17324738
Drug: Lisinopril (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (after 14 days)
Study: 15155205
Drug: Atazanavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (300 mg) and Ritonavir (100 mg) QD + Tenofovir DF QD (from day 15)
Study: 15155205
Drug: Atazanavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (300 mg) and Ritonavir (100 mg) QD
Study: 7991905
Drug: Propofol (1.5‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5‐2.5 mg/kg for induction; 6‐12 mg/kg continuous infusion for maintenance)
Study: 7991905
Drug: Neuroleptanalgesia (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptanalgesia (sodium thiopental 4‐5 mg/kg for induction; droperidol 0.15 microgram/kg/h and 50% N2O/O2 for maintenance)
Study: 2903110
Drug: Pentasa (5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa (5-aminosalicylic acid) 1500 mg t.i.d. (three times a day)